Steris Q2 profit beats expectations on healthcare strength

Steris

05/11/2025 21:41

Overview

Steris fiscal Q2 revenue grows 10%

Adjusted EPS for fiscal Q2 exceeds analyst estimates

Company raises fiscal 2026 outlook for organic revenue and adjusted EPS

Outlook

Company raises fiscal 2026 constant currency organic revenue growth to 7-8%

STERIS expects fiscal 2026 adjusted EPS to be $10.15-$10.30

Company anticipates fiscal 2026 free cash flow of approximately $850 mln

Result Drivers

HEALTHCARE SEGMENT - Healthcare revenue grew 9% driven by service and consumable sales, offset by tariff costs and inflation

APPLIED STERILIZATION TECHNOLOGIES - AST revenue rose 10% with growth in service revenue despite a decline in capital equipment sales

LIFE SCIENCES SEGMENT - Life Sciences revenue increased 13%, led by 39% growth in capital equipment sales

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted EPS
Beat
$2.47
$2.35 (8 Analysts)
Q2 Adjusted Net Income
Beat
$244.50 mln
$230.96 mln (5 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for STERIS plc is $280.00, about 13.6% above its November 4 closing price of $241.85

Press Release: ID:nGNX1YFQr5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)